Editorial: Might Astellas be the mystery bidder for Solvay's drug business?
This article was originally published in Scrip
Executive Summary
Much of the speculation swirling around the possible sale of Solvay's pharmaceutical business has one thing in common: that, along with Nycomed, the other serious bidder is a Japanese firm. But which one is it?